Study protocol: precision of a protocol for manual intramuscular needle placement checked by passive stretching and relaxing of the target muscle in the lower extremity during BTX-A treatment in children with spastic cerebral palsy, as verified by means of electrical stimulation

BMC Pediatrics

Jules Guilhelmus Becher¹  Roland Jeroen Vermeulen³  Jessica Warnink-Kavelaars² 

[1] Department of Rehabilitation Medicine, MOVE Research Institute Amsterdam, VU University Medical Centre, Boelelaan 1018, Amsterdam, the Netherlands;Division of Child and Adolescent Rehabilitation, Reade Centre for Rehabilitation and Rheumatology, Overtoom 283, Amsterdam, the Netherlands;Department of Child Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Boelelaan 1018, Amsterdam, the Netherlands

关键词: Injections;    Spasticity;    Cerebral palsy;    Children;    Electrical stimulation;    Botulinum toxin type-A;    Needle placement;   

Others  :  1144570
DOI  :  10.1186/1471-2431-13-129

 received in 2012-12-21, accepted in 2013-08-14,  发布年份 2013

【 摘 要 】

Background

Intramuscular injection of botulinum toxin type-A given by manual intramuscular needle placement in the lower extremity under general anaesthesia is an established treatment and standard of care in managing spasticity in children with spastic cerebral palsy. Optimal needle placement is essential. However, reports of injection and verification techniques used in previous studies have been partly incomplete and there are methodological shortcomings. This paper describes a detailed protocol for manual intramuscular needle placement checked by passive stretching and relaxing of the target muscle for each individual muscle injection location in the lower extremity during botulinum toxin type-A treatment under general anaesthesia in children with spastic cerebral palsy. It explains the design of a study to verify this protocol, which consists of an injection technique combined with a needle localizing technique, as by means of electrical stimulation to determine its precision.

Methods

Setting: University Medical Centre, Department of Paediatric Rehabilitation Medicine, the Netherlands.

Design: prospective observational study.

Participants: children with spastic cerebral palsy, aged 4 to 18 years, receiving regular botulinum toxin type-A treatment under general anaesthesia to improve their mobility, are recruited from the Department of Paediatric Rehabilitation Medicine at VU University Medical Centre, Amsterdam, the Netherlands.

Method: a detailed protocol for manual intramuscular needle placement checked by passive stretching and relaxing of the target muscle has been developed for each individual muscle injection location of the adductor brevis muscle, adductor longus muscle, gracilis muscle, semimembranosus muscle, semitendinosus muscle, biceps femoris muscle, rectus femoris muscle, gastrocnemius lateralis muscle, gastrocnemius medialis muscle and soleus muscle. This protocol will be verified as by means of electrical stimulation.

Technical details: 25 mm or 50 mm Stimuplex-needle and a Stimuplex-HNS-12 electrical stimulator will be used.

Discussion

Botulinum toxin type-A injected in the intended muscle is expected to yield the greatest effect in terms of activities. Protocols for manual intramuscular needle placement should be described in detail and verified to determine its precision. Detailed and verified protocols are essential to be able to interpret the results of botulinum toxin type-A treatment studies.

【 授权许可】

   
2013 Warnink-Kavelaars et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, et al.: Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 2005, 47(8):571-576.
• [2]Surveillance of Cerebral Palsy in Europe (SCPE): Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000, 42:816-824.
• [3]Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, et al.: Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology and the practice committee of the child neurology society. Neurology 2010, 74:336-343.
• [4]Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, Van CA, et al.: The updated European consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010, 14:45-66.
• [5]Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, et al.: The combined effect of lower-limb multilevel botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial. Arch Phys Med Rehabil 2006, 87:1551-1558.
• [6]Cosgrove AP, Corry IS, Graham HK: Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994, 36:386-396.
• [7]Barnes M: Botulinum toxin--mechanisms of action and clinical use in spasticity. J Rehabil Med 2003, 41:56-59.
• [8]Brin MF: Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997, 6:S146-S168.
• [9]Ade-Hall RA, Moore AP: Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database Syst Rev 2000, 2:CD001408.
• [10]Koman LA, Mooney JF III, Smith BP, Walker F, Leon JM, BOTOX Study Group: Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop 2000, 20:108-115.
• [11]Baker R, Jasinski M, Maciag-Tymecka I, Michalowska-Mrozek J, Bonikowski M, Carr L, et al.: Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002, 44:666-675.
• [12]Bjornson K, Hays R, Graubert C, Price R, Won F, McLaughlin JF, et al.: Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics 2007, 120:49-58.
• [13]Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, et al.: Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001, 108:1062-1071.
• [14]Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ: Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 1999, 10:1-9.
• [15]Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH: Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000, 83:481-487.
• [16]Chin TY, Nattrass GR, Selber P, Graham HK: Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop 2005, 25:286-291.
• [17]Haig AJ, Goodmurphy CW, Harris AR, Ruiz AP, Etemad J: The accuracy of needle placement in lower-limb muscles: a blinded study. Arch Phys Med Rehabil 2003, 84:877-882.
• [18]Xu K, Yan T, Mai J: A randomized controlled trial to compare two botulinum toxin injection techniques on the functional improvement of the leg of children with cerebral palsy. Clin Rehabil 2009, 23:800-811.
• [19]Kinnett D: Botulinum toxin A injections in children: technique and dosing issues. Am J Phys Med Rehabil 2004, 83:S59-S64.
• [20]Py AG, Zein AG, Perrier Y, Carlier RY, Picard A: Evaluation of the effectiveness of botulinum toxin injections in the lower limb muscles of children with cerebral palsy. Preliminary prospective study of the advantages of ultrasound guidance. Ann Phys Rehabil Med 2009, 52:215-223.
• [21]Yang EJ, Rha DW, Yoo JK, Park ES: Accuracy of manual needle placement for gastrocnemius muscle in children with cerebral palsy checked against ultrasonography. Arch Phys Med Rehabil 2009, 90:741-744.
• [22]O’Brien CF: Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve Suppl 1997, 6:S176-S180.
• [23]Schroeder AS, Berweck S, Lee SH, Heinen F: Botulinum toxin treatment of children with cerebral palsy - a short review of different injection techniques. Neurotox Res 2006, 9:189-196.
• [24]Berweck S, Feldkamp A, Francke A, Nehles J, Schwerin A, Heinen F: Sonography-guided injection of botulinum toxin A in children with cerebral palsy. Neuropediatrics 2002, 33:221-223.
• [25]Molloy FM, Shill HA, Kaelin-Lang A, Karp BI: Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology 2002, 58:805-807.
• [26]Bakheit AM: Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres. Eur J Neurol 2003, 10:415-419.
• [27]Albavera-Hernandez C, Rodriguez JM, Idrovo AJ: Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clin Rehabil 2009, 23:394-407.
• [28]Love SC, Novak I, Kentish M, Desloovere K, Heinen F, Molenaers G, et al.: Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol 2010, 17(Suppl 2):9-37.
• [29]Moore AP, Ade-Hall RA, Smith CT, Rosenbloom L, Walsh HP, Mohamed K, et al.: Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008, 71:122-128.
• [30]Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al.: Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2008, 70:1691-1698.